Meropenem
Trade name
Meropenem (GH), Meropenem (Juno), Meropenem (Kabi), Meropenem (Ranbaxy)
Presentation and preparation
|
Vial size
(powder volume) |
Fluid to add
|
Volume to add
|
Resulting concentration
|
|---|---|---|---|
| 500 mg (0.4 mL) |
Water for injections | 9.6 mL | 50 mg/mL |
| 1 g (0.9 mL) |
Water for injections | 19.1 mL | 50 mg/mL |
Reconstitute to 50 mg/mL and shake well, allowing it to stand until the solution is clear. Use reconstituted solution immediately.
IV administration
Give undiluted over 5 minutes or dilute to 1 to 20 mg/mL and infuse over 15 to 30 minutes.
IV infusion is preferred for doses of 40 mg/kg.
Neonates and infants less than 3 months: Give over at least 30 minutes.
Extended infusions may be considered for neonates, isolates with elevated MICs or in patients with critical illness. Refer to local guidelines.
Haemodialysis: Give at the end of haemodialysis.
Other routes of administration
IM: Not recommended.
SC: Not recommended.
Compatible IV fluids
Meropenem 1 mg/mL to 20 mg/mL:
Sodium chloride 0.9% is the preferred diluent for extended infusions.
Glucose 5% (3 hours only)
Glucose 5% and sodium chloride 0.9% (3 hours only)
Glucose 10% (2 hours only)
Y-site only and meropenem 20 mg/mL and 40 mg/mL:
Plasma-Lyte 148
Y-site only and meropenem 1 mg/mL to 20 mg/mL:
Potassium chloride 20 mmol/L
Additional information
Reconstituted solution should be colourless to pale yellow.
Reconstituted vial is stable for 12 hours if refrigerated. Discard unused vial contents.
Prepared infusions should be used immediately.